Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE220474 | GEO | 2022/12/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

Project description:Following nearly five decades with few approved therapies for acute myeloid leukemia (AML), the last three years have brought stellar progress with the U.S. Food and Drug Administration approving a number of new therapies for AML patients. Despite these advances, there are several high-risk patient AML populations with dismal survival on the order of months including those with primary refractory disease, those whose AML developed from an antecedent hematologic disorder, and those with high risk cytogenetic or mutational profiles (such as TP53 mutations or a complex karyotype). Furthermore, therapeutic options are limited for those unfit to receive cytotoxic chemotherapy due to age or co-morbidities. These treatment challenges clearly illustrate the need for improved therapeutic approaches in AML. Here we identify that antibody therapies for AML can be enhanced via optimization of (1) Fab target selection, and (2) engineering the Fc portion of the antibody to maximally engage receptors on immune effector cells. We demonstrate that antibodies targeting a novel AML-specific cell surface marker known as U5 snRNP200 have therapeutic efficacy in AML. Finally, we performed a whole-genome CRISPR screen to identify mechanisms by which U5 snRNP200 traffic to the cell surface. This revealed a requirement for cell-surface CD32a to enable U5 snRNP200 cell membrane localization.

2022-12-08 | GSE220473 | GEO

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]

2022-12-02 | GSE205028 | GEO

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies

Project description:Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies

| PRJNA909822 | ENA

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]

Project description:Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]

| PRJNA843099 | ENA

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

Project description:Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

| PRJNA909824 | ENA

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-03-16 | GSE222169 | GEO

Subtype-specific regulatory network rewiring in acute myeloid leukemia

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-09-20 | GSE108316 | GEO

IKAROS and MENIN are Functionally Cooperative Therapeutic Targets in Acute Myeloid Leukemia

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-03-10 | GSE168463 | GEO

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Project description:Acute myeloid leukemia (AML) is associated with a poor survival rate, and there is an urgent need for novel and more efficient therapies, ideally targeting AML stem cells that are essential for maintaining the disease. The interleukin 1 receptor accessory protein (IL1RAP; IL1R3) is expressed on candidate leukemic stem cells in the majority of AML patients, but not on normal hematopoietic stem cells. We show here that monoclonal antibodies targeting IL1RAP have strong antileukemic effects in xenograft models of human AML. We demonstrate that effector-cell-mediated killing is essential for the observed therapeutic effects and that natural killer cells constitute a critical human effector cell type. Because IL-1 signaling is important for the growth of AML cells, we generated an IL1RAP-targeting antibody capable of blocking IL-1 signaling and show that this antibody suppresses the proliferation of primary human AML cells. Hence, IL1RAP can be efficiently targeted with an anti-IL1RAP antibody capable of both achieving antibody-dependent cellular cytotoxicity and blocking of IL-1 signaling as modes of action. Collectively, these results provide important evidence in support of IL1RAP as a target for antibody-based treatment of AML.

| S-EPMC4553807 | biostudies-other

BET inhibition releases the Mediator complex from specific cis elements in acute myeloid leukemia cells

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-03-01 | E-GEOD-74651 | biostudies-arrayexpress